Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290043 | 0.85 | MGLL (0.58) | MGLL | |
| SCHEMBL29956374 | 0.85 | MGLL (0.58) | MGLL | |
| SCHEMBL15191227 | 0.77 | MGLL (0.58) | MGLL | |
| SCHEMBL2945825 | 0.77 | MGLL (0.58) | MGLLMAPT | |
| SCHEMBL16693111 | 0.77 | MGLL (0.58) | MGLLAPPKDM4EMEN1ALDH1A1 | |
| SCHEMBL29952719 | 0.77 | MGLL (0.58) | MGLLMAPT | |
| SCHEMBL8212 | 0.74 | MGLL (1.00) | MGLLAPP | |
| SCHEMBL17001366 | 0.74 | GFER (0.50) | GFERAXLAPPKDM4EMEN1 | |
| SCHEMBL1612576 | 0.73 | MGLL (0.53) | MGLLAPP | |
| SCHEMBL225978 | 0.73 | MGLL (0.53) | MGLLAPPMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20170327497-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-16 | — | — | US | disclosed |
| US-9663514-B2 | Substituted 6-aza-isoindolin-1-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2723739-B1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20150274723-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-01 | — | — | US | disclosed |
| US-9056873-B2 | Substituted 6-aza-isoindolin-1-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140206680-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-24 | — | — | US | disclosed |
| EP-2723739-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012177714-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-27 | — | — | WO | disclosed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | MGLL 2688/4885GFER 2826/4885AXL 2004/4885 |
| US-20150274723-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | SYK, MYD88, BTK | MGLL 4165/4885GFER 3595/4885AXL 598/4885 |
| US-20140206680-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | SYK, MYD88, BTK | MGLL 4165/4885GFER 3595/4885AXL 598/4885 |
| US-20170327497-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | SYK, MYD88, BTK | MGLL 4165/4885GFER 3595/4885AXL 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.